Eli Lilly and Company successfully challenged the domain foundayo-uk.store, which was used to impersonate the brand and offer unauthorized pharmaceutical products. The WIPO panel ordered the transfer of the domain to the Complainant following the Respondent’s failure to respond.
Case Snapshot
| Case Number | D2026-3678 |
|---|---|
| Complainant | Eli Lilly and Company |
| Respondent | jane Montegro |
| Disputed Domain | foundayo-uk.store |
| Threat Tactic | Fake Stores |
| Decision Date | 2026-09-11 |
| Panelist | Steven Auvil |
| Outcome | Transfer |
| Official Source | https://www.wipo.int/amc/en/domains/search/text.jsp?case=D2026-3678 |
Facing Unauthorized Domain Registrations or Brand Abuse?
Our domain dispute attorneys represent trademark owners and businesses worldwide before WIPO, Forum (NAF), and CAC. Explore our Domain Name Disputes and Enforcement & Takedowns services, or request a free case evaluation.
Request Case EvaluationBusiness and Security Risks of Pharmaceutical Impersonation
The registration and operation of the domain foundayo-uk.store presented significant risks to both the Complainant’s brand equity and consumer safety. By utilizing a geographic suffix to mirror legitimate regional presence, the Respondent created a deceptive platform that purported to sell pharmaceutical products under the FOUNDAYO mark. This tactic is particularly hazardous in the pharmaceutical sector, as it risks diverting consumers to unauthorized or potentially counterfeit products, including in jurisdictions where the Complainant’s medications have not been approved for distribution. Such activities threaten not only the financial interests of the brand owner but also the health and safety of patients who may be misled by the site’s official appearance.
Furthermore, the reliance on the ‘.store’ gTLD combined with the unauthorized use of the FOUNDAYO designation demonstrates a calculated effort to capitalize on the Complainant’s reputation for commercial gain. Even though the website was inactive by the time of the WIPO decision, the temporary nature of such sites often allows infringers to operate with minimal overhead while avoiding immediate detection by brand monitoring systems. This case underscores the necessity of proactive domain management and robust enforcement strategies, as the absence of a formal response from the Respondent indicates that these domains are frequently abandoned once challenged, leaving the brand owner to bear the burden of both investigative costs and the residual risk of traffic diversion.
Panel Reasoning: Confusing Similarity, Lack of Rights, and Bad Faith Findings
To secure the transfer of the disputed domain name under the UDRP, the Complainant satisfied the mandatory tripartite test set forth in Paragraph 4(a) of the Policy. The Panel determined that the domain foundayo-uk.store is confusingly similar to the Complainant’s registered FOUNDAYO trademark, noting that the inclusion of the geographic term ‘uk’ and the ‘.store’ gTLD does not mitigate the risk of confusion. This finding highlights the limited protection provided by appending geographic modifiers to established pharmaceutical trademarks in domain naming conventions, as such additions often fail to distinguish a site from the legitimate brand owner.
Regarding the second and third prongs, the Panel concluded that the Respondent lacked any rights or legitimate interests in the disputed domain. The evidence demonstrated that the Respondent was neither affiliated with nor authorized by Eli Lilly to utilize the FOUNDAYO mark. Instead, the domain was deployed to offer unauthorized or potentially counterfeit pharmaceutical products to a global audience. The Respondent’s failure to submit a formal response to the complaint left these allegations of unauthorized commercial activity uncontested, allowing the Panel to weigh the evidence firmly against the respondent.
Finally, the Panel found that the registration and use of the domain constituted bad faith. By operating a website that mimicked an official storefront to deceive consumers into believing there was a corporate affiliation with the Complainant, the Respondent sought to derive commercial gain through consumer confusion. This strategy of exploiting brand equity for the sale of unauthorized goods serves as a clear indication of bad faith registration. Consequently, the Panel’s decision to order the transfer of the domain underscores the policy’s efficacy in addressing digital impersonation and protecting consumers from illicit pharmaceutical e-commerce sites.
Strategic Breakdown: Addressing Pharmaceutical Impersonation and Geographic Misdirection
The Complainant’s strategy effectively leveraged the structural manipulation of the disputed domain, ‘foundayo-uk.store,’ to establish a clear case of bad faith. By documenting the respondent’s use of a geographic suffix combined with a generic TLD to create a veneer of localized legitimacy, the Complainant successfully argued that the domain was designed to deceive consumers. The strategy focused on providing the panel with direct evidence of an impersonation-based ‘fake shop,’ highlighting how the site mirrored the brand’s commercial identity to offer unauthorized pharmaceuticals. This evidence, combined with the respondent’s failure to provide any defense or documentation of legitimate commercial interest, simplified the panel’s assessment of bad faith registration and use.
Furthermore, the efficacy of the Complainant’s case relied on establishing a clear nexus between their registered FOUNDAYO trademark and the respondent’s unauthorized activity. By citing the specific timing of the trademark registration and contrasting it against the domain’s resolution to a site purporting to sell identical, albeit counterfeit, goods, the Complainant minimized the potential for ambiguity regarding intent. The decision underscores that for brand owners, maintaining a record of the infringing site’s content—even if it becomes inactive during the dispute process—is essential for proving that a domain was specifically crafted for commercial gain through affiliation misrepresentation. This approach solidifies the argument that the respondent’s sole purpose was to profit from the misappropriation of established pharmaceutical branding.
Practical Recommendations
- Prioritize proactive monitoring of brand-related keywords paired with high-risk geographic identifiers (e.g., ‘-uk’) and e-commerce TLDs like ‘.store’ to detect infringing fake shops early.
- Document evidence of unauthorized product offerings, specifically highlighting global availability and lack of regulatory approval, to satisfy the ‘bad faith’ use requirement under UDRP.
- Utilize standardized ‘cease and desist’ notices in conjunction with UDRP filings to establish a pattern of respondent behavior, even when the respondent is likely to abandon the domain without a formal response.
- Maintain centralized records of official corporate websites and authorized distribution channels to strengthen the argument against unauthorized affiliation claims during panel review.
- Leverage the ‘confusingly similar’ criteria by documenting how minimal additions, such as a country suffix combined with a generic store TLD, create a high likelihood of consumer confusion for pharmaceutical brands.
Frequently Asked Questions (FAQ)
Why was the domain ‘foundayo-uk.store’ considered confusingly similar to Eli Lilly’s brand?
The WIPO panel found the domain confusingly similar because it incorporated the ‘FOUNDAYO’ trademark in its entirety, merely appending the geographic indicator ‘-uk’ and the generic TLD ‘.store’, which creates a clear risk of consumer confusion regarding the site’s official affiliation.
How did the panel determine that the respondent had no rights or legitimate interests in the domain?
The panel concluded the respondent lacked legitimate interests as they were unauthorized to use the FOUNDAYO mark, and the domain was actively used to solicit sales of counterfeit or gray-market pharmaceutical products, which does not constitute a bona fide offering of goods.
What evidence established the respondent’s bad faith in this case?
Bad faith was proven by the respondent’s operation of a website that explicitly mimicked the brand to trick users into believing it was an official channel, paired with the respondent’s decision to abandon the UDRP process by failing to submit a formal response.
What is the primary takeaway for brand protection strategy from this ruling?
This case highlights the importance of monitoring geographic and e-commerce-specific domain suffixes. Even if a site goes inactive during the proceedings, a UDRP filing remains an effective mechanism to secure the transfer of domains used for fraudulent impersonation.
Found a fake shop using your brand?
Protect your pharmaceutical brand equity and consumer safety. If you have identified unauthorized sites selling counterfeit products under your trademark, our experts can provide a UDRP eligibility assessment to help you initiate a domain recovery strategy.
This case note is for informational purposes only and is not legal advice.
